Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 119 articles:
HTML format

Single Articles

    November 2022
  1. JACKSON S, Kabir Z, Comiskey C
    Impact of universal tuberculosis vaccination cessation on the epidemiology of paediatric tuberculosis cases in Ireland from 2011 to 2021.
    Lancet. 2022;400 Suppl 1:S53.
    PubMed     Abstract available

  2. ISBA R, Brennan L, Davies N, Knight J, et al
    Measles, mumps, and rubella vaccination coverage in children younger than 5 years attending a paediatric emergency department in Manchester, UK: a cross-sectional observational study.
    Lancet. 2022;400 Suppl 1:S51.
    PubMed     Abstract available

  3. BURNS R, Campos-Matos I, Harron K, Aldridge RW, et al
    COVID-19 vaccination uptake for half a million non-EU migrants and refugees in England: a linked retrospective population-based cohort study.
    Lancet. 2022;400 Suppl 1:S5.
    PubMed     Abstract available

  4. HUF SW, Woldmann L, Crespo RF, Grailey K, et al
    Implementing behavioural science informed letter interventions to increase COVID-19 vaccination uptake in uncontactable London residents: a difference-in-difference study in London, UK.
    Lancet. 2022;400 Suppl 1:S41.
    PubMed     Abstract available

    October 2022
  5. AGUS DB, Nguyen A, Sall AA, Bell J, et al
    COVID-19 and other adult vaccines can drive global disease prevention.
    Lancet. 2022 Oct 27. pii: S0140-6736(22)02084.

  6. OPEL DJ, Brewer NT, Buttenheim AM, Callaghan T, et al
    The legacy of the COVID-19 pandemic for childhood vaccination in the USA.
    Lancet. 2022 Oct 26. pii: S0140-6736(22)01693.

  7. AGRAWAL U, Bedston S, McCowan C, Oke J, et al
    Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.
    Lancet. 2022;400:1305-1320.
    PubMed     Abstract available

  8. MSELLATI P, Sow K, Desclaux A, Cottrell G, et al
    Reconsidering the COVID-19 vaccine strategy in West and Central Africa.
    Lancet. 2022;400:1304.

    September 2022
  9. HAMEED SS, Hall E, Grange Z, Sullivan C, et al
    Characterising adults in Scotland who are not vaccinated against COVID-19.
    Lancet. 2022;400:993-995.

  10. ZIEGLER T, Moen A, Zhang W, Cox NJ, et al
    Global Influenza Surveillance and Response System: 70 years of responding to the expected and preparing for the unexpected.
    Lancet. 2022;400:981-982.

    August 2022
  11. UYEKI TM, Hui DS, Zambon M, Wentworth DE, et al
    Lancet. 2022;400:693-706.
    PubMed     Abstract available

  12. HILL M, Bandyopadhyay AS, Pollard AJ
    Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use.
    Lancet. 2022 Aug 18. pii: S0140-6736(22)01582.

    July 2022
    Perilous two-tier COVID-19 global vaccine roll-out.
    Lancet. 2022 Jul 11. pii: S0140-6736(22)01284.

  14. MELLO MM, Opel DJ, Benjamin RM, Callaghan T, et al
    Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA.
    Lancet. 2022 Jul 8. pii: S0140-6736(22)00875.

    June 2022
  15. SACCO C, Del Manso M, Mateo-Urdiales A, Rota MC, et al
    Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
    Lancet. 2022 Jun 30. pii: S0140-6736(22)01185.
    PubMed     Abstract available

    COVID-19 vaccination for children aged 5-11 years.
    Lancet. 2022 Jun 30. pii: S0140-6736(22)01245.

  17. LI G, Cappuccini F, Marchevsky NG, Aley PK, et al
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Lancet. 2022;399:2212-2225.
    PubMed     Abstract available

  18. WONG HL, Hu M, Zhou CK, Lloyd PC, et al
    Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Lancet. 2022;399:2191-2199.
    PubMed     Abstract available

  19. PATEL M, Patel M
    Increasing children's global access to COVID-19 vaccines.
    Lancet. 2022;399:2171-2173.

  20. HUSBY A, Kober L
    COVID-19 mRNA vaccination and myocarditis or pericarditis.
    Lancet. 2022;399:2168-2169.

    May 2022
  21. SASIENI P, Castanon A
    HPV vaccination and cervical cancer screening - Authors' reply.
    Lancet. 2022;399:1940.

  22. BEWLEY S
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939.

  23. KAMAMOTO S, Murayama A, Hamaki T, Kusumi E, et al
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939-1940.

    Eliminating cholera in Haiti.
    Lancet. 2022;399:1928-1929.

  25. DZAU VJ, Balatbat CA, Offodile AC 2nd
    Closing the global vaccine equity gap: equitably distributed manufacturing.
    Lancet. 2022 May 6. pii: S0140-6736(22)00793.

    April 2022
    Africa CDC warns COVID-19 vaccine production could cease.
    Lancet. 2022;399:1683.

  27. NGUYEN-TRAN H, Messacar K
    Preventing enterovirus A71 disease: another promising vaccine for children.
    Lancet. 2022 Apr 12. pii: S0140-6736(22)00380.

  28. NGUYEN TT, Chiu CH, Lin CY, Chiu NC, et al
    Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2022 Apr 12. pii: S0140-6736(22)00313.
    PubMed     Abstract available

  29. BUCHBINDER SP, McElrath MJ, Dieffenbach C, Corey L, et al
    COVID-19 vaccination and HIV-1 acquisition - Authors' reply.
    Lancet. 2022;399:e36.

  30. LOGUNOV DY, Livermore DM, Ornelles DA, Bayer W, et al
    COVID-19 vaccination and HIV-1 acquisition.
    Lancet. 2022;399:e34-e35.

  31. MENNI C, Valdes AM, Polidori L, Antonelli M, et al
    Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
    Lancet. 2022 Apr 7. pii: S0140-6736(22)00327.
    PubMed     Abstract available

  32. WINTER AK, Moss WJ
    Lancet. 2022;399:1336-1346.
    PubMed     Abstract available

  33. KHOBRAGADE A, Bhate S, Ramaiah V, Deshpande S, et al
    Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.
    Lancet. 2022;399:1313-1321.
    PubMed     Abstract available

  34. BLAKNEY AK, Bekker LG
    DNA vaccines join the fight against COVID-19.
    Lancet. 2022;399:1281-1282.

    March 2022
  35. KRAUSE PR, Rees H, Figueroa JP, Swaminathan S, et al
    Booster vaccines for COVID-19 vaccine breakthrough cases? - Authors' reply.
    Lancet. 2022;399:1225.

  36. NIXON DF, Schwartz RE, Ndhlovu LC
    Booster vaccines for COVID-19 vaccine breakthrough cases?
    Lancet. 2022;399:1224.

  37. BEKKER LG, Garrett N, Goga A, Fairall L, et al
    Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.
    Lancet. 2022;399:1141-1153.
    PubMed     Abstract available

  38. USHER AD
    CEPI launches 100-day vaccine "moonshot".
    Lancet. 2022;399:1107-1108.

  39. REARTE A, Castelli JM, Rearte R, Fuentes N, et al
    Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
    Lancet. 2022 Mar 15. pii: S0140-6736(22)00011.
    PubMed     Abstract available

  40. MILLS EJ, Reis G
    Evaluating COVID-19 vaccines in the real world.
    Lancet. 2022 Mar 15. pii: S0140-6736(22)00194.

  41. MANCA T, Baylis F, Munoz FM, Top KA, et al
    Prioritise research on vaccines for pregnant and breastfeeding women.
    Lancet. 2022;399:890-893.

  42. FALLAH MP, Reinhart E
    Apartheid logic in global health.
    Lancet. 2022;399:902-903.

  43. NUNEZ I
    Vaccine approval before phase 3 trial results: a consequence of vaccine access inequity.
    Lancet. 2022 Mar 2. pii: S0140-6736(22)00164.

    February 2022
  44. CHEMAITELLY H, Abu-Raddad LJ
    Waning effectiveness of COVID-19 vaccines.
    Lancet. 2022;399:771-773.

  45. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
    Lancet. 2022 Feb 24. pii: S0140-6736(21)02867.
    PubMed     Abstract available

  46. BAJAJ SS, Maki L, Stanford FC
    Vaccine apartheid: global cooperation and equity.
    Lancet. 2022 Feb 23. pii: S0140-6736(22)00328.

  47. PIECHOTTA V, Harder T
    Waning of COVID-19 vaccine effectiveness: individual and public health risk.
    Lancet. 2022 Feb 21. pii: S0140-6736(22)00282.

  48. FEIKIN DR, Higdon MM, Abu-Raddad LJ, Andrews N, et al
    Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.
    Lancet. 2022 Feb 21. pii: S0140-6736(22)00152.
    PubMed     Abstract available

  49. KALAFAT E, Magee LA, von Dadelszen P, Heath P, et al
    COVID-19 booster doses in pregnancy and global vaccine equity.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00166.

  50. MADHI SA, Ihekweazu C, Rees H, Pollard AJ, et al
    Decoupling of omicron variant infections and severe COVID-19.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00109.

  51. EGGER S, Egger G
    The vaccinated propor-tion of people with COVID-19 needs context.
    Lancet. 2022;399:627.

    Stigma, vaccination, and moral accountability.
    Lancet. 2022;399:626-627.

    Ayoade Alakija: advancing equity in the COVID-19 response.
    Lancet. 2022;399:511.

  54. BURKI T
    Fresh questions over Gates Foundation governance.
    Lancet. 2022;399:508.

  55. BEYRER C
    Archbishop Desmond Tutu and the universality of health and human rights.
    Lancet. 2022;399:503-504.

  56. NORDSTROM P, Ballin M, Nordstrom A
    Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.
    Lancet. 2022 Feb 4. pii: S0140-6736(22)00089.
    PubMed     Abstract available

  57. KARAFILLAKIS E, Van Damme P, Hendrickx G, Larson HJ, et al
    COVID-19 in Europe: new challenges for addressing vaccine hesitancy.
    Lancet. 2022 Feb 3. pii: S0140-6736(22)00150.

  58. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021.
    Lancet. 2022 Feb 1. pii: S0140-6736(22)00172.
    PubMed     Abstract available

    January 2022
  59. JAFFE S
    The next steps for US vaccine mandates.
    Lancet. 2022;399:425-426.

  60. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.
    Lancet. 2022 Jan 27. pii: S0140-6736(22)00101.
    PubMed     Abstract available

  61. HUBSCHEN JM, Gouandjika-Vasilache I, Dina J
    Lancet. 2022 Jan 27. pii: S0140-6736(21)02004.
    PubMed     Abstract available

  62. FENDLER A, Shepherd STC, Au L, Wu M, et al
    Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.
    Lancet. 2022 Jan 25. pii: S0140-6736(22)00147.

  63. LANE R
    Jamal Rifi: family doctor building bridges in the community.
    Lancet. 2022;399:353.

  64. COSTA CLEMENS SA, Weckx L, Clemens R, Almeida Mendes AV, et al
    Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00094.
    PubMed     Abstract available

  65. BRAVO L, Smolenov I, Han HH, Li P, et al
    Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00055.
    PubMed     Abstract available

    Trimeric S protein COVID-19 vaccine needs to find its place.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00096.

  67. CARR EJ, Wu M, Harvey R, Billany RE, et al
    Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00104.

  68. WU M, Wall EC, Carr EJ, Harvey R, et al
    Three-dose vaccination elicits neutralising antibodies against omicron.
    Lancet. 2022 Jan 19. pii: S0140-6736(22)00092.

  69. KUHLMANN C, Mayer CK, Claassen M, Maponga T, et al
    Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
    Lancet. 2022 Jan 18. pii: S0140-6736(22)00090.

    December 2021
  70. KING J, Ferraz OLM, Jones A
    Mandatory COVID-19 vaccination and human rights.
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02873.

  71. HALPERIN SA, Ye L, MacKinnon-Cameron D, Smith B, et al
    Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02753.
    PubMed     Abstract available

    Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine.
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02834.

  73. LEUNG K, Wu JT
    Managing waning vaccine protection against SARS-CoV-2 variants.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02841.

  74. KATIKIREDDI SV, Cerqueira-Silva T, Vasileiou E, Robertson C, et al
    Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02754.
    PubMed     Abstract available

  75. PEELING RW, Heymann DL, Teo YY, Garcia PJ, et al
    Diagnostics for COVID-19: moving from pandemic response to control.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02346.
    PubMed     Abstract available

  76. MCINTYRE PB, Aggarwal R, Jani I, Jawad J, et al
    COVID-19 vaccine strategies must focus on severe disease and global equity.
    Lancet. 2021 Dec 16. pii: S0140-6736(21)02835.

  77. STUART ASV, Shaw RH, Liu X, Greenland M, et al
    Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
    Lancet. 2021 Dec 6. pii: S0140-6736(21)02718.
    PubMed     Abstract available

    Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19.
    Lancet. 2021 Dec 6. pii: S0140-6736(21)02757.

  79. KARIM SSA, Karim QA
    Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.
    Lancet. 2021 Dec 3. pii: S0140-6736(21)02758.

  80. MENDELSON M, Venter F, Moshabela M, Gray G, et al
    The political theatre of the UK's travel ban on South Africa.
    Lancet. 2021 Dec 3. pii: S0140-6736(21)02752.

  81. MUNRO APS, Janani L, Cornelius V, Aley PK, et al
    Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
    Lancet. 2021 Dec 2. pii: S0140-6736(21)02717.
    PubMed     Abstract available

    November 2021
  82. JAFFE S
    Legal challenges threaten Biden's COVID-19 vaccine rule.
    Lancet. 2021;398:1863-1864.

  83. BURKI T
    mRNA discoveries earn the 2021 Prince Mahidol Award.
    Lancet. 2021;398:1865.

  84. OMER SB, Benjamin RM, Brewer NT, Buttenheim AM, et al
    Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02507.
    PubMed     Abstract available

  85. PAVORD S, Scully M, Lester W, Makris M, et al
    Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?
    Lancet. 2021;398:1801.

  86. BHUYAN P, Medin J, da Silva HG, Yadavalli M, et al
    Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply.
    Lancet. 2021;398:1801-1802.

  87. LAZARUS R, Baos S, Cappel-Porter H, Carson-Stevens A, et al
    Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02329.
    PubMed     Abstract available

  88. ELLA R, Reddy S, Blackwelder W, Potdar V, et al
    Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02000.
    PubMed     Abstract available

  89. LI JX, Zhu FC
    Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02014.

  90. ALVES L
    Health experts welcome Brazil COVID-19 inquiry findings.
    Lancet. 2021;398:1674-1675.

  91. USHER AD
    New budget and strategy for ACT-A.
    Lancet. 2021;398:1677.

    WHO's Tedros set to be re-elected unopposed.
    Lancet. 2021;398:1676.

  93. ORTIZ JR, Neuzil KM
    The value of vaccine programme impact monitoring during the COVID-19 pandemic.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02322.

  94. MCNAMARA LA, Wiegand RE, Burke RM, Sharma AJ, et al
    Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02226.
    PubMed     Abstract available

  95. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
    The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
    PubMed     Abstract available

    October 2021
  96. HODGES S, Hornberger J, Kufakurinani U, Rudra S, et al
    When suspicion replaces evidence in public health.
    Lancet. 2021;398:1565-1566.

  97. BARDA N, Dagan N, Cohen C, Hernan MA, et al
    Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
    Lancet. 2021 Oct 29. pii: S0140-6736(21)02249.
    PubMed     Abstract available

  98. GRANGE Z, Buelo A, Sullivan C, Moore E, et al
    Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland.
    Lancet. 2021 Oct 28. pii: S0140-6736(21)02316.

  99. SONABEND R, Whittles LK, Imai N, Perez-Guzman PN, et al
    Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Lancet. 2021 Oct 27. pii: S0140-6736(21)02276.
    PubMed     Abstract available

  100. USHER AD
    Vaccine shortages prompt changes to COVAX strategy.
    Lancet. 2021;398:1474.

  101. HILLSON K, Clemens SC, Madhi SA, Voysey M, et al
    Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination.
    Lancet. 2021 Oct 21. pii: S0140-6736(21)02282.

    Cautious optimism for malaria vaccine roll-out.
    Lancet. 2021;398:1394.

  103. SAAG MS
    Developing COVID-19 vaccine policy in increments.
    Lancet. 2021;398:1382-1383.

    Malaria vaccine approval: a step change for global health.
    Lancet. 2021;398:1381.

  105. PRENDECKI M, Thomson T, Clarke CL, Martin P, et al
    Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02096.

  106. TARTOF SY, Slezak JM, Fischer H, Hong V, et al
    Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02183.
    PubMed     Abstract available

    September 2021
    COVID-19: learning as an interdependent world.
    Lancet. 2021;398:1105.

  108. LANE R
    Gagandeep Kang: helping to shape a healthier India.
    Lancet. 2021;398:947.

  109. ALIBERTI S, Dela Cruz CS, Amati F, Sotgiu G, et al
    Community-acquired pneumonia.
    Lancet. 2021;398:906-919.
    PubMed     Abstract available

  110. FLAXMAN A, Marchevsky NG, Jenkin D, Aboagye J, et al
    Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01699.
    PubMed     Abstract available

    August 2021
  111. USHER AD
    Health leaders criticise limited ACT-A review.
    Lancet. 2021;398:650-651.

    July 2021
  112. KICKBUSCH I, Leung GM, Shattock RJ
    Learning from crisis: building resilient systems to combat future pandemics.
    Lancet. 2021;398:e2-e6.

    June 2021
    Colombians protest over inequities and health care.
    Lancet. 2021;397:2454.

  114. USHER AD
    A beautiful idea: how COVAX has fallen short.
    Lancet. 2021;397:2322-2325.

  115. USHER AD
    ACT Accelerator strains donors' aid budgets.
    Lancet. 2021;397:2137.

    May 2021
  116. SAXENA SG, Godfrey T
    Catalysing needed change for health systems in the USA.
    Lancet. 2021;397:1705-1706.

  117. REINHART E, Dawes D, Maybank A
    Structural medicine: towards an economy of care.
    Lancet. 2021;397:1691-1693.

    March 2021
    Myanmar's democracy and health on life support.
    Lancet. 2021;397:1035.

  119. DEVI S
    Health in Syria: a decade of conflict.
    Lancet. 2021;397:955-956.

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.